Transforming Molecular Diagnostics through NanoTechnology

Projektinformationen

UbiHealth

ID Finanzhilfevereinbarung: 101188322

DOI

10.3030/101188322

EK-Unterschriftsdatum 20 November 2024

Startdatum 1 Dezember 2024

Enddatum 30 November 2026

Finanziert unter

• The European Innovation Council (EIC)

Gesamtkosten

Keine Daten

EU-Beitrag

€ 2 499 999,00

Koordiniert durch

ALTRATECH LIMITED
Ireland

Periodic Reporting for period 1 - UbiHealth (Transforming Molecular Diagnostics through NanoTechnology)

Berichtszeitraum: 2024-12-01 bis 2025-11-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Project Summary
Altratech introduce a completely new method of molecular detection. This is a first-of-kind, multianalyte DNA, RNA, antibody and antigen diagnostic. It delivers concurrent serology and nucleic acid detection. The technology is compliant with the challenging demands of WHO REASSURED criteria, especially in providing a commercially viable diagnostic tool for the developing world.
The innovation is in the process of being productised by our sub-contractor The Cambridge Design Partnership (UK) into a fully automated, portable, stand-alone instrument for Point of Care and Point of Need. It will not require medically qualified personnel to operate. This innovation provides substantial advantages over existing, more complex, expensive and less portable Point of Care systems for the management of viral infections such as HIV, Hepatitis, Influenza, Malaria, Meningitis, Shingles, Dengue Fever, HPV, EBV-related cancers, and many more.
The Value Proposition to our target customers, who will be the world’s leading diagnostic companies, is the ability to licence a novel patent protected product, with a wider range of market applications compared to their current diagnostic products. This will facilitate their entry into new markets and increase gross margins in existing markets. This innovation will impact the €48B Diagnostics industry.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

•Isothermal (Recombinase Polymerase Amplification) protocol developed, detecting down to 1000 copies/mL from whole blood, and four other concentrations from whole blood and plasma.
•A filtration system provided a practical method of plasma separation and using this workflow, reliably detected HIV RNA at 1,000 copies/mL on the Altratech CMOS chip cartridge.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Altratech Detection Cartridge showed greater sensitivity than gold-standard optical detection at very low copy numbers (≥ 50 copies/mL).